Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Asset Writedowns and Impairment: 2012-2025

Historic Asset Writedowns and Impairment for Veracyte (VCYT) over the last 5 years, with Jun 2025 value amounting to $20.5 million.

  • Veracyte's Asset Writedowns and Impairment was N/A to $20.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $23.9 million, marking a year-over-year change of. This contributed to the annual value of $3.4 million for FY2024, which is 95.07% down from last year.
  • As of Q2 2025, Veracyte's Asset Writedowns and Impairment stood at $20.5 million, which was up 644.55% from $2.8 million recorded in Q4 2024.
  • Over the past 5 years, Veracyte's Asset Writedowns and Impairment peaked at $34.9 million during Q3 2023, and registered a low of $185,000 during Q3 2024.
  • Over the past 3 years, Veracyte's median Asset Writedowns and Impairment value was $2.8 million (recorded in 2024), while the average stood at $13.2 million.
  • Data for Veracyte's Asset Writedowns and Impairment shows a maximum YoY crashed of 99.47% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Veracyte's Asset Writedowns and Impairment stood at $3.3 million in 2022, then reached $32.0 million in 2023, then plummeted by 91.40% to $2.8 million in 2024, then reached $20.5 million in 2025.
  • Its Asset Writedowns and Impairment stands at $20.5 million for Q2 2025, versus $2.8 million for Q4 2024 and $185,000 for Q3 2024.